Welcome to our dedicated page for Satellos Bioscience news (Ticker: MSCLF), a resource for investors and traders seeking the latest updates and insights on Satellos Bioscience stock.
Satellos Bioscience Inc. develops clinical-stage biotechnology programs for degenerative muscle diseases, led by SAT-3247, an orally administered small molecule therapy designed to restore natural muscle repair and regeneration. Company news centers on Duchenne muscular dystrophy clinical development, including Phase 2 BASECAMP pediatric and TRAILHEAD adult studies, AAK1 biology, muscle-force and biomarker data, and research publications supporting its stem-cell-based approach.
Updates also cover regulatory clearances, scientific and investor conference presentations, board and leadership appointments, public financing activity, share consolidation, and exchange-listing developments tied to the company's common shares.
Satellos Bioscience announced its Q1 2024 financial and operational results.
Key highlights include preclinical advancements and GMP manufacturing for SAT-3247, with Phase 1 clinical trials on track to start mid-2024.
The company reported a cash balance of $33.2 million as of March 31, 2024, down from $39.6 million at the end of 2023.
Net loss for Q1 2024 was $6.9 million, significantly higher than the $1.7 million loss in Q1 2023, due to increased R&D and G&A expenses.
Satellos also received Orphan Drug status from the FDA for SAT-3247 and plans to present at the PPMD conference in June 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.